Shabnam Anjum | Nanotechnology in Medicine and Healthcare | Research Excellence Award

Dr. Shabnam Anjum | Nanotechnology in Medicine and Healthcare | Research Excellence Award

Post-Doctorate | Shenzhen University | India

Dr. Shabnam Anjum is a postdoctoral researcher at Shenzhen University with a strong research footprint in biomaterials, nanofibrous scaffolds, extracellular vesicles, and regenerative medicine. Her work focuses extensively on the design, fabrication, and optimization of nanofibers, nanoparticles, microspheres, and hydrogels for tissue regeneration, particularly targeting bone, tendon, and ligament repair. She has contributed significantly to the advancement of electrospinning-based nanofibrous scaffolds, developing bioinspired core–shell systems, multifunctional drug-delivery constructs, and biomimetic matrices capable of modulating osteogenic and osteoclastic activity. Her publications in high-impact journals, including ACS Nano, Materials Today Bio, Frontiers in Bioengineering and Biotechnology, International Journal of Biological Macromolecules, and International Journal of Molecular Sciences, highlight her expertise in biomaterials, stem cell–derived extracellular vesicles, nanostructured drug-delivery systems, and regenerative therapeutics. She has authored influential review articles and innovative research papers demonstrating optimized electrospinning strategies, bioactive scaffold architectures, and decellularized matrix-based regenerative platforms. Her published findings collectively record 250 Scopus citations, 9 documents, and an h-index of 7. Dr. Shabnam Anjum’s emerging research pipeline includes cutting-edge studies on extracellular vesicle engineering, spatiotemporal therapeutic delivery, and osteoporotic bone regeneration. Her technical strengths span electrospinning, nanoparticle synthesis, advanced material characterization, microCT analysis, western blotting, qPCR, flow cytometry, and comprehensive biological evaluations. She has presented her research at prestigious scientific events such as the Chinese Biomaterials Conference and has actively engaged in global scientific webinars covering cancer research, stem cell biology, and precision medicine. She has also contributed to the scientific community through participation in specialized training programs on nanomaterials, animal experimentation, and polymer processing. Her research has been recognized through notable scholarships and academic distinctions, reflecting her dedication to innovative biomaterial development and regenerative therapy. Dr. Shabnam Anjum’s contributions continue to support advancements in nanotechnology-enabled regenerative medicine, positioning her as a promising researcher in the fields of tissue engineering, biomaterials design, and therapeutic nanotechnology.

Profiles: Scopus | Google Scholar | ResearchGate | Sci Profiles | Scilit | Loop

Featured Publications

1. Anjum, S., Rahman, F., Pandey, P., Arya, D. K., Alam, M., Rajinikanth, P. S., & Ao, Q. (2022). Electrospun biomimetic nanofibrous scaffolds: A promising prospect for bone tissue engineering and regenerative medicine. International Journal of Molecular Sciences, 23(16), 9206. https://doi.org/10.3390/ijms23169206

2. Kanaujiya, S., Arya, D. K., Pandey, P., Singh, S., Pandey, G., Anjum, S., … Rajinikanth, P. S. (2024). Resveratrol-ampicillin dual-drug loaded polyvinylpyrrolidone/polyvinyl alcohol biomimic electrospun nanofiber enriched with collagen for efficient burn wound repair. International Journal of Nanomedicine, 19, 5397–5418. https://doi.org/10.2147/IJN.S464046

3. Anjum, S., Wang, Y., Xin, Y., Li, X., Li, T., Zhang, H., Quan, L., Li, Y., Arya, D. K., … Ao, Q. (2024). Bioinspired core-shell nanofiber drug-delivery system modulates osteogenic and osteoclast activity for bone tissue regeneration. Materials Today Bio, 26, 101088. https://doi.org/10.1016/j.mtbio.2024.101088

4. Anjum, S., Li, T., Saeed, M., & Ao, Q. (2024). Exploring polysaccharide and protein-enriched decellularized matrix scaffolds for tendon and ligament repair: A review. International Journal of Biological Macromolecules, 254, 127891. https://doi.org/10.1016/j.ijbiomac.2023.127891

5. Arya, D. K., Deshpande, H., Kumar, A., Chidambaram, K., Pandey, P., Anjum, S., … Pandey, G. (2024). HER-2 receptor and αvβ3 integrin dual-ligand surface-functionalized liposome for metastatic breast cancer therapy. Pharmaceutics, 16(9), 1128. https://doi.org/10.3390/pharmaceutics16091128

Yi Yao | Nanomedicine | Best Researcher Award

Prof. Yi Yao | Nanomedicine | Best Researcher Award

Renmin Hospital of Wuhan University | China

Prof. Yi Yao is a distinguished oncologist, Ph.D., Chief Physician, and Director of the Cancer Center at Renmin Hospital of Wuhan University, China, with a career dedicated to advancing cancer treatment and research. He earned his medical degree and doctorate from Wuhan University and received international training as a Visiting Scholar at the German Cancer Research Center, Heidelberg University, and MD Anderson Cancer Center in the United States. His clinical and research interests focus on tumor radiotherapy and the tumor immune microenvironment, with particular emphasis on how irradiation influences tumor biology, radiotherapy efficacy, and radiation-induced lung injury, including the role of fibroblasts and tumor interstitial fibrosis in treatment outcomes. Prof. Yao has secured major research funding from the National Natural Science Foundation of China, the Hubei Natural Science Foundation, and multiple institutional projects, while building collaborations with world-leading cancer research centers in Germany and the United States. He has published extensively in high-impact journals such as Nature Communications, The EMBO Journal, Journal of Clinical Oncology, Cancer Medicine, Histopathology, Nano Letters, and Frontiers in Immunology, in addition to co-editing oncology volumes and holding software copyrights. Recognized with numerous national, provincial, and institutional awards for his contributions to research, clinical practice, and mentorship, Prof. Yao serves on national and provincial oncology committees, is a member of ASCO and ESMO, and continues to mentor doctoral and master’s students, making lasting contributions to oncology education, clinical innovation, and cancer research.

Profile: Orcid

Featured publications

  • Zhang, H., Chen, L., Li, L., Liu, Y., Das, B., Zhai, S., Tan, J., Jiang, Y., Turco, S., Yao, Y., & Frishman, D. (2025). Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning. NPJ Precision Oncology, 9(1), 76.

  • Dong, Y., Khan, L., & Yao, Y. (2024). Immunological features of EGFR-mutant NSCLC and clinical practice. Journal of the National Cancer Center, 4(4), 289–298.

  • Yi, L., Wen, Y., Xiao, M., Yuan, J., Ke, X., Zhang, X., Khan, L., Song, Q., & Yao, Y. (2024). The proportion of tumour stroma predicts response to immune checkpoint inhibitor plus chemotherapy in stage IIIB–IV NSCLC. Histopathology, 85(2), 295–309.

  • Yao, Y., Shen, Y., Yao, J. C., & Zuo, X. (2024). Editorial: New advancement in tumor microenvironment remodeling and cancer therapy. Frontiers in Cell and Developmental Biology, 12, 1384567.

  • Li, Y., Chen, J., Wang, B., Xu, Z., Wu, C., Ma, J., Song, Q., Geng, Q., Yu, J., Pei, H., & Yao, Y. (2023). FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resistance Updates, 67, 100926.

  • Yao, Y., Chu, Y., & Xu, B. (2019). Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Medicine, 8(2), 554–563.